Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Dhara N. Amin"'
This file contains supplementary figures including the western blots corresponding to the schematics of figures 2,3,4,5, as well as additional data sets referred to in the paper.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07fe7389135ceb86b8f63aa9453b4851
https://doi.org/10.1158/1535-7163.22503030
https://doi.org/10.1158/1535-7163.22503030
Autor:
Michael Klagsbrun, Antonio Iavarone, Anna Lasorella, Akio Shimizu, Dhara N. Amin, Silvia Coma
Supplementary Figures 1-3, Tables 1-2 from Id2 Promotes Tumor Cell Migration and Invasion through Transcriptional Repression of Semaphorin 3F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::493b4b8ca8ef5bb88262b4ad3ffe8de1
https://doi.org/10.1158/0008-5472.22385919.v1
https://doi.org/10.1158/0008-5472.22385919.v1
Autor:
Young Hwan Chang, James Korkola, Dhara N Amin, Mark M Moasser, Jose M Carmena, Joe W Gray, Claire J Tomlin
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0121607 (2015)
With the advent of high-throughput measurement techniques, scientists and engineers are starting to grapple with massive data sets and encountering challenges with how to organize, process and extract information into meaningful structures. Multidime
Externí odkaz:
https://doaj.org/article/14a785c35c624705972b50641381164b
Autor:
Hui Zhang, Nathaniel Gulizia, Catherine C. Park, Mark M. Moasser, Julie Oeffinger, Deepika Ahuja, Ana Ruiz-Saenz, Dhara N. Amin, Shabnam Ziaee, Marcia R. Campbell
Publikováno v:
Breast Cancer Research and Treatment. 155:431-440
The central role of HER2 as the disease driver and HER3 as its essential partner has made them rational targets for the treatment of HER2-amplifed breast cancers, and there is considerable interest in developing highly effective treatment regimens fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b4d2bbf44bd6af9f9d3e5a04d2454a7
https://doi.org/10.1007/s10549-016-3698-y
https://doi.org/10.1007/s10549-016-3698-y
Publikováno v:
Molecular cancer therapeutics, vol 14, iss 12
The requisite role of HER3 in HER2-amplified cancers is beyond what would be expected as a dimerization partner or effector substrate and it exhibits a substantial degree of resiliency that mitigates the effects of HER2-inhibitor therapies. To better
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cab6d7a25486e46b2ef5e9ddbdaede0
https://doi.org/10.1158/1535-7163.mct-15-0403
https://doi.org/10.1158/1535-7163.mct-15-0403
Autor:
Scott E. Martin, Paula Marlton, Vinit G. Karur, YiMeng Chang, Christopher Arthur, Christopher R. Flowers, Raghuveer Singh Mali, Tycel Phillips, Deepak Sampath, Uwe Hahn, Dhara N. Amin, MaryAnn Go, Jamie Hirata, Ingrid E. Wertz, Monica Tani, Rajat Bannerji, Matthew T. Chang, Maxwell M. Krem, Lisa Musick, Andrew Polson, Sam Yuen Yuen, Jason Oeh, Victoria Pham, Elizabeth A. Lasater, Shang-Fan Yu, Christopher M. Rose, Eva Lin, Giuseppe Gritti, John F. Seymour, Anna M. Johnston, Anuradha Zindal, Nadia Khan
Publikováno v:
Cancer Research. 80:CT133-CT133
Purpose: Treatment of patients with relapsed or refractory lymphoid neoplasms represents a significant clinical challenge, largely due to the genetic heterogeneity of these malignancies. Our study goal was to design a rational treatment strategy that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af1eff2ca981a30d1d3f71efd37d326d
https://doi.org/10.1158/1538-7445.am2020-ct133
https://doi.org/10.1158/1538-7445.am2020-ct133
Autor:
Joachim Rudolph, Thomas Hunsaker, Christiaan Klijn, Christine Orr, Matthew R. Durk, Scott E. Martin, Dhara N. Amin, Mark Merchant, Frances Shanahan, Yihong Yu, Richard M. Neve, Xiaolin Zhang, Amy Gustafson, John Chan, Shiva Malek, Hank La, Eva Lin, Avinashnarayan Venkatanarayan, Ivana Yen, Scott A. Foster
Publikováno v:
Cancer cell. 34(4)
Targeting KRAS mutant tumors through inhibition of individual downstream pathways has had limited clinical success. Here we report that RAF inhibitors exhibit little efficacy in KRAS mutant tumors. In combination drug screens, MEK and PI3K inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ddade1c5e7ca4e5c18047266180c322
https://pubmed.ncbi.nlm.nih.gov/30300582
https://pubmed.ncbi.nlm.nih.gov/30300582
Publikováno v:
Oncotarget
The clinical impact of HER2 inhibitors in the treatment of HER2-amplified breast cancers has been largely confined to chemotherapy combination regimens, since HER2 inhibitors appear to have very modest efficacies by themselves. This is due to the res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b5b45daab27ee344960fc19f2ac00a1
https://doi.org/10.18632/oncotarget.5660
https://doi.org/10.18632/oncotarget.5660
Publikováno v:
Seminars in Cell & Developmental Biology. 21:944-950
Many types of human cancer are characterized by deregulation of the human epidermal growth factor receptor (HER) family of tyrosine kinase receptors. In some cancers, genomic events causing overactivity of individual HER family members are etiologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6017fc662bfb9a8c1c7927831b7b233c
https://doi.org/10.1016/j.semcdb.2010.08.007
https://doi.org/10.1016/j.semcdb.2010.08.007
Autor:
Jamie Hirata, Jason Oeh, Andy Polson, Deepak Sampath, Dhara N. Amin, Anuradha Zindal, Ingrid E. Wertz, Mehrdad Mobasher, Lisa Musick
Publikováno v:
Cancer Research. 78:880-880
Venetoclax, a potent, orally bioavailable inhibitor that selectively targets BCL-2 and induces intrinsic apoptosis, is currently approved for the treatment of relapsed/refractory chronic lymphocytic leukemia with 17p deletion (R/R 17p del CLL) and al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79610fad8fe2a9db402c2e61c857a68d
https://doi.org/10.1158/1538-7445.am2018-880
https://doi.org/10.1158/1538-7445.am2018-880